At what enterprise value was DOC GENERICI acquired in 2019?

During the acquisition of DOC GENERICI by ICG / MERIEUX EQUITY PARTNERS in 2019, the company was valued at an estimated revenue multiple of 5x - 12x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of DOC GENERICI when it was acquired by ICG / MERIEUX EQUITY PARTNERS?

The estimated EV/EBITDA multiple for DOC GENERICI is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was DOC GENERICI acquired by ICG / MERIEUX EQUITY PARTNERS?

DOC GENERICI was acquired by ICG / MERIEUX EQUITY PARTNERS in 2019.

What was the revenue of DOC GENERICI at the time of the deal?

The revenue of DOC GENERICI at the time of the deal is estimated to be in the range of 150M - 250M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of DOC GENERICI during the acquisition?

DOC GENERICI's EBITDA is estimated to be in the range of 50M - 100M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the DOC GENERICI acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the DOC GENERICI deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.fusacq.com/buzz/freppel-imprimeur-rejoint-le-groupe-stratus-packaging-a257678_fr_

← DATABASE

Home Database Healthcare & PharmaDOC GENERICI

04/2019

DOC GENERICI acquired by ICG & MERIEUX EQUITY PARTNERS

ITALY Life Sciences / Pharma & Biotech / Generics / Labs EV 1b - 4b EUR

Context

ICG acquired 100% of DOC Generici from CVC Capital Partners, marking the company's third private equity cycle. Merieux Equity Partners joined as a strategic co-investor to leverage its industrial expertise in life sciences. The deal was financed by a syndicate of banks including UniCredit, BNP Paribas, Credit Agricole, and Barclays. The investment thesis was built on DOC's resilient "asset-light" business model, which delivers high margins and strong cash flow conversion. Under ICG's ownership, the group aims to further expand its product pipeline and potentially explore international M&A to diversify its purely Italian revenue base.

In the past, the company had already been the subject of several LBOs, notably led by Charterhouse in 2013 and Cvc in 2016. This succession of buyouts highlights the strong attractiveness of the company's business model.

DOC GENERICI, which reported an EBITDA margin of in 2018, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

DOC Generici is Italy's leading independent generic pharmaceutical company. It operates an asset-light model, focusing on the marketing and distribution of a vast portfolio of out-of-patent drugs across multiple therapeutic areas (cardiovascular, gastrointestinal, metabolic). It holds one of the largest market shares in the Italian retail pharmacy channel.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2018

2017

Other operations with DOC GENERICI

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
07/2022	TPG	DOC GENERICI	ITALY	Generics / Labs
03/2016	CVC	DOC GENERICI	ITALY	Generics / Labs
07/2013	CHARTERHOUSE	DOC GENERICI	ITALY	Generics / Labs

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 150M - 250M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DOC GENERICI by ICG / MERIEUX EQUITY PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: icg / merieux equity partners